Factors that were associated with significantly worse PFS in multivariable analysis in the entire cohort included prior anti-BCMA targeting agent (HR 1.60, p = 0.0090), baseline ferritin ≥ upper quartile (HR 2.00, p = 0.0010), baseline CRP ≥ upper quartile (HR 1.61, p = 0.0146), baseline Hb <8 (HR 1.90, p = 0.0032) and presence of either plasma cell leukemia (HR 4.93, p = 0.0128) or EMD (HR 1.67, p = 0.0048) prior to start of Tec. This evidence concerns the gene GSTM1 and plasma cell leukemia.